® SUPPLEMENT May 2020 THE AMERICAN JOURNAL OF MANAGED CARE® Vol. 26 • No. 5, Sup. Improving Treatment Strategies for Wet Age-Related Macular Degeneration HIGHLIGHTS › Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden › Managed Care Opportunities and Approaches to Select Treatment for Sight Preservation › CE Sample Posttest Supplement to The American Journal of Managed Care® © 2020 Managed Care & Healthcare Communications, LLC Improving Treatment Strategies for Wet Age-Related Macular Degeneration Release date: May 15, 2020 clinical trial results. Some patients will continue to require monthly anti- Expiration date: May 15, 2021 VEGF injections after 10 years of treatment, which can threaten adherence. Medicare shoulders the burden of paying for neovascular AMD, and Estimated time to complete activity: 2.0 hours rising costs of drug therapy must be considered along with the growing Type of activity: Application demand for treatment. Continuing education will improve managed care Medium: Print with Internet-based posttest, evaluation, and request professionals’ and pharmacists’ competency in managing AMD through for credit a greater insight into the new treatment modalities and strategies to Fee: Free optimize treatment. This activity is supported by an educational grant from Genentech. Educational Objectives Upon completion of this activity, participants will be able to: Intended Audience • Outline the epidemiology, pathophysiology, and disease burden of Pharmacists and managed care professionals neovascular AMD and explore the impact of technological advancements in AMD diagnosis and monitoring. Activity Overview • Examine clinical efficacy and safety, dosage regimens, and unique attri- Age-related macular degeneration (AMD), an eye disease with an onset in butes of current and emerging anti-VEGF agents for neovascular AMD. later life, is a leading cause of visual impairment and blindness both in • Identify anti-VEGF treatment regimens that minimize the injection the United States and around the world. Over the past 15 years, intravitreal burden in neovascular AMD. anti-vascular endothelial growth factor (VEGF) agents have revolution- • Explore factors that affect the delivery of cost-effective therapy to patients ized the management of neovascular AMD. Improvements in vision with neovascular AMD. preservation and quality of life come with a cost: regular office visits for monitoring and for intravitreal anti-VEGF injections, and financial Accreditation Statement strain. This activity will enable managed care pharmacists to have a better Pharmacy Times Continuing Education™ is accredited by the understanding of new treatment modalities and strategies to optimize Accreditation Council for Pharmacy Education (ACPE) as a treatment in neovascular AMD. provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal Statement of Educational Need activity number 0290-0000-20-061-H01-P. The activity is available for CE More than 11 million Americans are living with age-related macular credit through March 16, 2021. degeneration (AMD), an eye disease of the elderly population that causes a progressive loss of the central vision that is needed to drive, read, recog- Obtaining Credit: Participants must read the article, then complete the nize faces, and see the world in color. AMD can progress quickly, with online posttest, an online evaluation, and request for credit. Detailed vision deteriorating within days of clinical manifestation. Over the past 15 instructions on obtaining CE credit are included at the end of this activity. years, intravitreal anti-vascular endothelial growth factor (VEGF) agents have revolutionized the management of neovascular AMD. Based on clin- This CE activity is also offered free online at www.ajmc.com/ce and ical trial data, at least 95% of patients are expected to remain within 3 at www.PharmacyTimes.org/go/wet-amd-suppl, where you will be lines of their baseline visual acuity after 2 years of treatment with an anti- directed to the activity in its entirety, including the online pretest and VEGF agent; however, vision preservation in the real world falls short of posttest, activity evaluation, and request for credit. Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements. MAY 2020 www.ajmc.com ® SUPPLEMENT May 2020 THE AMERICAN JOURNAL OF MANAGED CARE® Vol. 26 • No. 5, Sup. Improving Treatment Strategies for Wet Age-Related Macular Degeneration TABLE OF CONTENTS OVERVIEW Through this supplement to The American Journal of Managed Participating Faculty S102 Care®, managed care profes- sionals will increase their Reports knowledge of advances in treat- ment of wet age-related macular Wet Age-Related Macular Degeneration: Treatment Advances degeneration, including the to Reduce the Injection Burden S103 potential cost implications of new treatment modalities. Caroline R. Baumal, MD Managed Care Opportunities and Approaches to Select Treatment for Sight Preservation S112 Winston Wong, PharmD CE Sample Posttest S118 A Supplement to The American Journal of Managed Care® PROJ ACE0161 THE AMERICAN JOURNAL OF MANAGED CARE® Supplement VOL. 26, NO. 5 S101 FACULTY & DISCLOSURE FACULTY EDITORIAL & PRODUCTION Senior Vice President Medical Writers Caroline R. Baumal, MD Winston Wong, PharmD Jeff Prescott, PharmD, RPh Amber Schilling, Professor President PharmD Assistant Director, Tufts University School of Medicine W-Squared Group Valerie Sjoberg Content Services Boston, Massachusetts Longboat Key, Florida Angelia Szwed Samantha Stone, PhD Scientific Directors Copy Chief Danielle Jamison, Jennifer Potash PharmD, MS Copy Supervisor MEDICAL WRITING & EDITORIAL SUPPORT Darria Zangari, Paul Silverman PharmD, BCPS, BCGP Jill E. Allen, PharmD, BCPS Elizabeth Paczolt, MD, FACNM Medical & Scientific Senior Clinical Quality Review Editor Medical Writer and Drug Information Consultant Consultant Medical Writer/Director Project Managers Stacey Abels, PhD Pin Oak Associates Churchville, Pennsylvania Ida Delmendo Copy Editors Salt Lake City, Utah Danielle Mroz, MA Georgina Carson Clinical Project Rachelle Laliberte Managers Kirsty Mackay Lauren Burawski, MA Amy Oravec FACULTY DISCLOSURES Ted Pigeon Creative Director, Project Managers Publishing Caroline R. Baumal, MD, has the following Winston Wong, PharmD, has no relevant Lindsay Caporrino Ray Pelesko relevant financial relationships with commercial financial relationships with commercial interests Andrea Szeszko Senior Art Director interests to disclose: to disclose. Associate Editors Melissa Feinen Consultancies or paid advisory boards: Hayley Fahey Art Director Genentech, Novartis, Ocular Therapeutics Jill Pastor Julianne Costello Amanda Thomas Lecture fees: Genentech, Novartis, Zeiss. SALES & MARKETING Vice President National Account MEDICAL WRITING & EDITORIAL SUPPORT DISCLOSURES Gil Hernandez Managers Pharmacy Times Continuing Education™ Robert Foti Jill E. Allen, PharmD, BCPS, and Elizabeth Senior National Ryan O’Leary Paczolt, MD, FACNM, have no relevant Planning Staff: Jim Palatine, RPh, MBA; Maryjo Account Managers Ben Baruch National Account financial relationships with commercial interests Dixon, RPh; Kimberly Simpson, PharmD; Olivia Megan Halsch Associate to disclose. Mastrodonato; Susan Pordon; and Brianna Kevin George Winters have no relevant financial relationships The American Journal of Managed Care® with commercial interests to disclose. OPERATIONS & FINANCE Publishing Staff: Ida Delmendo, Ted Pigeon, Angelia Szwed, Monica Tran, Elizabeth Kukielka, Circulation Director Vice President, and Andrea Szeszko have no relevant financial Jon Severn Finance relationships with commercial interests to disclose. circulationmjhassoc.com Leah Babitz, CPA Controller Katherine Wyckoff DISCLOSURE POLICY CORPORATE According to the disclosure policy of The Continuing Education™ to initiate a mechanism ® Chairman & Founder Senior Vice President, American Journal of Managed Care and Pharmacy to resolve the conflict(s). The existence of these Mike Hennessy Sr I.T. & Enterprise Times Continuing Education™, all persons who relationships is not viewed as implying bias or Systems Vice Chairman are in a position to control content are required decreasing the value of the activity. All educa- John Moricone Jack Lepping to disclose any relevant financial relationships tional materials are reviewed for fair balance, Senior Vice President, President & CEO with commercial interests. If a conflict is identi- scientific objectivity of studies reported, and Mike Hennessy Jr Audience Generation & fied, it is the responsibility of Pharmacy Times levels of evidence. Product Fulfillment Chief Financial Officer Joy Puzzo Neil Glasser, CPA/CFE Vice President, Executive Vice Human Resources DISCLOSURE OF UNAPPROVED/OFF-LABEL USE President, Operations